-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
![Screenshot 2024-03-27 084228](https://volition.com/wp-content/uploads/2024/03/Screenshot-2024-03-27-084228.png)
Circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti EZH2-based treatment in advanced solid tumour patients
- Share
- Tweet
- Share on Facebook
- Share
![Screenshot 2024-03-27 083745](https://volition.com/wp-content/uploads/2024/03/Screenshot-2024-03-27-083745.png)
![Screenshot 2024-03-27 083745](https://volition.com/wp-content/uploads/2024/03/Screenshot-2024-03-27-083745.png)
Poster titled: Circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti EZH2-based treatment in advanced solid tumour patients: translational analyses from CAIRE trial
Presented at: AACR 2024
Salani et al
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields